A clinical trial led by scientists at Harvard Medical School showed that the drug retratutide helped obese people lose an average of 24% of their original weight in 48 weeks. The result means that the effectiveness of the drug is higher than analogues: Ozempic and Vegovi. Research published New England Journal of Medicine.
The study included 338 obese people. Random injections of retratutide or placebo were given.
On average, subjects taking the highest dose of retatrutide lost more than 17% of their body weight at week 24 and more than 24% of their weight by week 48. This is equivalent to an average of 27 kg over the 11 months of the study. For comparison, the average weight loss in the placebo group was only about 2%. Participants in the trials reported a decrease in appetite or a faster onset of satiety.
Scientists said earlier comparable results from last year’s clinical trials of the diabetes drug Mounjaro (Tirzepatide) resulted in an average weight loss of more than 22% after 72 weeks of use. But 24% weight loss with a single drug has never been seen before.
Retatrutide acts on three different gut hormones that are stimulated by food intake. These hormones play a role in controlling appetite and energy expenditure. One of them is targeted by the drug Ozempic, and the other two are targeted by the substance tirzepatid, the active ingredient in the diabetes drug Mounjaro.
Now the drug awaits the third phase of clinical trials. It will take at least two years, after which the drug can be approved for sale.
The clinical trial was conducted by retatrutide developer Eli Lilly and Co. funded by.
ancient scientists to solveAn increase in heart rate to 140 beats per minute can cause a stroke if the carotid arteries are narrowed by 50% or more.